For research use only. Not for therapeutic Use.
Fazpilodemab（Cat No.:I042106）is an investigational monoclonal antibody targeting the immune checkpoint protein TIGIT (T-cell immunoreceptor with Ig and ITIM domains). It is being developed to modulate the immune system by blocking TIGIT, which plays a role in suppressing T-cell activity and promoting immune evasion by tumors. By inhibiting TIGIT, fazpilodemab aims to enhance anti-tumor immune responses and improve the efficacy of immune checkpoint therapies in cancer. It is being studied in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and other solid tumors, to evaluate its safety and effectiveness.
| Catalog Number | I042106 |
| CAS Number | 2517935-02-1 |
| Purity | ≥95% |
